Search Results By Date:
Showing 31 - 45 of 613 results
  • Shour A, Onitilo AA. Distance Matters: Investigating No-Shows in a Large Rural Provider Network. Clin Med Res. 2023 December;21(4):177-191. doi: 10.3121/cmr.2023.1853.
    PubMed ID: 38296643
  • Unger JM, Stires H, Levit LA, Stewart M, McKelvey BA, Canin B,...Schenkel C [including Onitilo AA.] Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality. JCO Oncol Pract. 2023 October;19(10):907-916. doi: 10.1200/OP.23.00185. PMCID: PMC10615547.
    PubMed ID: 37643386
  • Nycz G, Glurich I, Dunkel R, Springer T, Ryan M, Shimpi N. Chronic Oral Diseases. Chronic Disease Epidemiology, Prevention, and Control 5th Edition. American Public Health Association; 2023: 767-794.
  • Shour AR, Jones GL, Anguzu R, Doi SA, Onitilo AA. Development of an evidence-based model for predicting patient, provider, and appointment factors that influence no-shows in a rural healthcare system. BMC Health Serv Res. 2023 September 14; 23(1):989. doi: 10.1186/s12913-023-09969-5. PMCID: PMC10503036.
    PubMed ID: 37710258
  • Joseph A, Akinsete A, Adeneye S, Balogun O, Awofeso O, Oladipo A,...Onitilo AA [including Puthoff D, Shour A.] Feasibility and Safety of Implementing Volumetric Arc Therapy (VMAT) for Pediatric Craniospinal Irradiation in a Low-Middle-Income Region: The Nigerian Experience. Advances in Radiation Oncology. 2023 July 28; :101325. doi: 10.1016/j.adro.2023.101325.
  • Bulen BJ, Khazanov NA, Hovelson DH, Lamb LE, Matrana M, Burkard ME,...Tomlins SA [including Onitilo AA.] Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit. Cancer Res Commun. 2023 July; 3(7):1335-1349. doi: 10.1158/2767-9764.CRC-23-0036. PMCID: PMC10367935.
    PubMed ID: 37497337
  • Navari RM, Le-Rademacher J, Smieliauskas F, Ruddy KJ, James Saphner T, Liu H,...Loprinzi CL [including Onitilo AA.] Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602). [published online ahead of print 2023 June 7]. Oncologist. doi: 10.1093/oncolo/oyad140.
    PubMed ID: 37284847
  • Shour A, onitilo AA, Anguzu R. The impact of minority health social vulnerability on population-based cancer incidence. [published online ahead of print 2023 May 25]. JOURNAL OF CLINICAL ONCOLOGY. 41(16):e22501. doi: 10.1200/JCO.2023.41.16\_suppl.e22501.
  • Panich J, Irwin C, Bissonette A, Elkhidir S, Lodhi F, Folz C,...Kattamanchi S [including Lee J, Pulipati S, Fatima Z, Gopinath P, Blonsky R, Abboud Leon C.] Cohort study on immune checkpoint inhibitor-associated acute kidney injury: Incidence, risk factors, and management strategies. J Oncol Pharm Pract. 2023 April 26;10781552231171078. doi: 10.1177/10781552231171078.
    PubMed ID: 37125423
  • Shour AR, Anguzu R, Zhou Y, Muehlbauer A, Joseph A, Oladebo T,...Onitilo AA [including Puthoff D.] Your neighborhood matters: an ecological social determinant study of the relationship between residential racial segregation and the risk of firearm fatalities. BioMed Central Injury Epidemiology Journal. 2023 March 13; 10(14)doi: 10.1186/s40621-023-00425-w. PMCID: PMC10012477.
    PubMed ID: 36915201
  • Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR,...Onitilo AA. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 March 2; 388(9):813-823.
    PubMed ID: 36856617
  • Joseph A, Shour AR, Lasebikan NN, Jimoh MA, Adegboyega BC, Nwachukwu E,...Onitilo AA [including Puthoff D.] Examining Cancer Patients' Perceptions of the Impact of COVID-19 on Teleoncology: Findings From 15 Nigerian Outpatient Cancer Clinics. JCO Glob Oncol. 2023 March;9:e2200221. doi: https://doi.org/10.1200/go.22.00221. PMCID: PMC10497253.
    PubMed ID: 36921242
  • Onitilo AA, Shour AR, Puthoff DS, Tanimu Y, Joseph A, Sheehan MT. Evaluating the adoption of voice recognition technology for real-time dictation in a rural healthcare system: A retrospective analysis of dragon medical one. PLoS One. 2023 March;18(3):e0272545. doi: 10.1371/journal.pone.0272545. PMCID: PMC10035815.
    PubMed ID: 36952436
  • Shimpi N, Glurich I, Gabor R, Chyou PH, Nycz G, Acharya A. Impact of Establishing Dental Access for Preventable Infectious Dental Diseases (PIDD) in Medical Settings: Case Study from Rural Wisconsin. Community Dent Health. 2023 February 28;40(1):23-29. doi: 10.1922/CDH_00102Shimpi07.
    PubMed ID: 36269067
  • Tomlins SA, Khazanov NA, Bulen BJ, Hovelson DH, Shreve MJ, Lamb LE,...Rhodes DR [including Onitilo AA.] Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. Commun Med (Lond). 2023 February 7; 3(1):14. PMCID: PMC9905474.
    PubMed ID: 36750617